Table 2.
miRNA-221 expression analysis by (a) one way ANOVA followed by (b) Post hoc test multiple comparisons for Tukey’s HSD.
| (a) | ||||||
|---|---|---|---|---|---|---|
| Groups | Sum of squares | df | Mean square | F | Significance | |
| Between groups | 22,821.606 | 2 | 11,410.803 | 40.984 | 0.00012* | |
| Within groups | 15,870.012 | 57 | 278.421 | |||
| Total | 38,691.618 | 59 | ||||
| (b) | ||||||
|---|---|---|---|---|---|---|
| Group A | Group B | Mean difference (A-B) | Std. error | Significance | 95% confidence interval | |
| Lower bound | Upper bound | |||||
| Control | MNG | − 3.64700 | 5.27656 | 0.770 | − 16.3446 | 9.0506 |
| Thyroid Cancer Patients | − 43.07450** | 5.27656 | 0.000 | − 55.7721 | − 30.3769 | |
| MNG | Control | 3.64700 | 5.27656 | 0.770 | − 9.0506 | 16.3446 |
| Thyroid Cancer Patients | − 39.42750** | 5.27656 | 0.000 | − 52.1251 | − 26.7299 | |
| Thyroid Cancer Patients | Control | 43.07450** | 5.27656 | 0.000 | 30.3769 | 55.7721 |
| MNG | 39.42750** | 5.27656 | 0.000 | 26.7299 | 52.1251 | |
*Significance at the 0.05 level.
**The mean difference is significant at the 0.05 level.